Table 1. Relevant vaccine policies and events.
| Peak | Note | Date | Events |
|---|---|---|---|
| I | a | 2020-01-26 | The Chinese Center for Disease Control and Prevention has begun developing the COVID-19 vaccine |
| b | 2020-02-25 | The world’s first mRNA drug development company has opened the safety clinical trial | |
| c | 2020-03-17 | Recombinant COVI-19 vaccine approved for clinical trials | |
| II | d | 2020-06-04 | China’s NHC Director Ma Xiaowei attended a video conference of the Global Vaccine Summit |
| e | 2020-06-18 | Circular on the issuance of general biosafety requirements for vaccine production workshops | |
| f | 2020-08-11 | Russia has announced the registration of the world’s first COVID-19 vaccine | |
| g | 2020-08-17 | China’s first patent for COVID-19 vaccine was approved | |
| h | 2020-10-16 | Preliminary clinical trial results of a COVID-19 inactivated vaccine in China have been published in the Lancet | |
| i | 2020-10-20 | The coronavirus mutation had no substantial impact on vaccine development | |
| 2020-10-20 | COVID-19 vaccine development schedule, priority population, and pricing | ||
| III | j | 2020-12-06 | Five COVID-19 vaccines were tested in phase III clinical trials in China |
| k | 2020-12-19 | Introduction of COVID-19 vaccination in key populations | |
| 2020-12-19 | Vaccination population, location, price, adverse reactions, expiration date, safety of the COVID-19 vaccine | ||
| l | 2020-12-21 | The situation of epidemic prevention and control and vaccination of key groups in winter and spring were introduced | |
| m | 2020-12-31 | China’s first COVID-19 vaccine has been conditionally released and free for all | |
| n | 2021-01-09 | The COVID-19 vaccine is free for all | |
| o | 2021-01-31 | The incidence of severe abnormal reactions reported with COVID-19 vaccines was not higher than with influenza vaccines | |
| IV | p | 2021-02-25 | The State Food and Drug Administration approved the application for registration of recombinant COVID-19 vaccine (adenovirus type 5 vector) of Consino Biosciences with conditions |
| 2021-02-25 | COVID-19 inactivated vaccine (Vero cell) from Sinopharm Wuhan Company was approved by The State Food and Drug Administration with conditions | ||
| q | 2021-03-15 | How long will it take to get other vaccines after the COVID-19 vaccine | |
| r | 2021-03-22 | Mass vaccination of people over the age of 60 will be launched | |
| s | 2021-03-29 | Official technical guidelines for vaccination are issued after 100 million people have been vaccinated | |
| 2021-03-29 | The introduction of COVID-19 vaccination: it should be carried out as soon as possible, promoted step by step, prioritized, and safeguarded | ||
| 2021-03-29 | Technical Guidelines for COVID-19 Vaccination (first edition) | ||
| V | t | 2021-04-29 | Cross-regional vaccination efforts |
| u | 2021-05-14 | Interpretation of the COVID-19 Prevention and Control Plan (Version 8) | |
| v | 2021-05-17 | Deployment of COVID-19 prevention and control and COVID-19 vaccination | |
| w | 2021-05-30 | People’s Daily online released a popular map of COVID-19 vaccination | |
| x | 2021-06-18 | The NHC has deployed COVID-19 prevention and control and COVID-19 vaccination efforts |
The letters a–x are similar in Figures 1,2. COVID-19, coronavirus disease of 2019; mRNA, messenger RNA; NHC, National Health Commission.